Rucaparib was the first PARP-1 inhibitor to enter clinical trials [30] and olaparib was the first PARP-1 inhibitor to gain FDA approval for the treatment of germline BRCA-deficient ovarian cancer. The gene discussed is PARP1; the disease is ovarian cancer.